LeRoy EC (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22(4):675–694
Sunderkotter C, Riemekasten G (2006) Pathophysiology and clinical consequences of Raynaud’s phenomenon related to systemic sclerosis. Rheumatology (Oxford) 45(Suppl 3):iii33–iii35
Riemekasten G, Sunderkotter C (2006) Vasoactive therapies in systemic sclerosis. Rheumatology (Oxford) 45(Suppl 3):iii49–iii51
Foerster J, Fleischanderl S, Wittstock S, Storch A, Meffert H, Riemekasten G, Worm M (2005) Infrared-mediated hyperthermia is effective in the treatment of scleroderma-associated Raynaud’s phenomenon. J Invest Dermatol 125(6):1313–1316
Jahr S, Schoppe B, Reisshauer A (2008) Effect of treatment with low-intensity and extremely low-frequency electrostatic fields (Deep Oscillation) on breast tissue and pain in patients with secondary breast lymphoedema. J Rehabil Med 40(8):645–650
Yocum DE, Hodes R, Sundstrom WR, Cleeland CS (1985) Use of biofeedback training in treatment of Raynaud’s disease and phenomenon. J Rheumatol 12(1):90–93
Wilson E, Belar CD, Panush RS, Ettinger MP (1983) Marked digital skin temperature increase mediated by thermal biofeedback in advanced scleroderma. J Rheumatol 10(1):167–168
Freedman RR, Ianni P, Wenig P (1984) Behavioral treatment of Raynaud’s phenomenon in scleroderma. J Behav Med 7(4):343–353
Malenfant D, Catton M, Pope JE (2009) The efficacy of complementary and alternative medicine in the treatment of Raynaud’s phenomenon: a literature review and meta-analysis. Rheumatology (Oxford) 48(7):791–795 Epub 2009 May 11